Evaluation of Pulpal and Salivary Neuropeptides in Dental Pain
NCT ID: NCT07330024
Last Updated: 2026-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
72 participants
OBSERVATIONAL
2024-11-01
2025-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salivary Immune/Stress Biomarkers Among Children
NCT05021380
Success of Inferior Alveolar Nerve Block in Women Taking Selective Serotonin Reuptake Inhibitors
NCT02884596
Perineural and Systemic Dexamethasone Use in Dental Surgeries in Terms of Anesthesia Duration and Postop Complaints
NCT06318013
Comparison of Anesthetic Efficacy of Mental Nerve Block Versus Inferior Alveolar Nerve Block in Mandibular Anterior Teeth and Premolars in Symptomatic Irreversible Pulpitis
NCT06333730
Evaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block Effectiveness
NCT07146997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This observational cross-sectional study includes adult participants who require endodontic treatment and are categorized into painful and painless groups based on clinical examination and pain assessment using the Verbal Rating Scale (VRS). Pulp tissue samples are obtained during routine endodontic access procedures, and unstimulated saliva samples are collected before and after the clinical procedure. Levels of SP and CGRP in pulp and saliva samples are measured using enzyme-linked immunosorbent assay (ELISA).
Psychological status is evaluated using the Depression Anxiety Stress Scale-21 (DASS-21) to assess levels of depression, anxiety, and stress. Pulpal inflammation is evaluated through histopathological examination of pulp tissue samples using a semi-quantitative scoring system.
The primary objective of this study is to evaluate the relationship between dental pain and pulpal and salivary neuropeptide levels. Secondary objectives include assessing the associations between neuropeptides, psychological status, pain severity, and histopathological pulpal inflammation. The study is designed to provide descriptive and associative data without intervention, supporting a biopsychosocial framework for understanding dental pain and exploring the potential clinical relevance of salivary biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Painful Group
Participants presenting with dental pain who require endodontic treatment and report pain based on clinical examination and Verbal Rating Scale assessment.
No interventions assigned to this group
Painless Group
Participants without dental pain who require endodontic treatment and report no pain based on clinical examination and Verbal Rating Scale assessment.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA physical status I or II
* Presence of permanent teeth requiring endodontic treatment
* Ability to understand the study procedures and provide written informed consent
* No use of analgesic medications within 24 hours prior to clinical assessment
* No food or drink intake within 2 hours prior to saliva sampling
Exclusion Criteria
* Systemic inflammatory, autoimmune, neuropathic, or chronic pain disorders
* Acute infection, fever, or antibiotic use within the last 7 days
* Pregnancy or lactation
* Regular use of psychiatric medications (e.g., antidepressants, anxiolytics, antipsychotics, antiepileptics)
* Tobacco use or alcohol consumption within the last 24 hours
* Previous endodontic treatment or history of dental trauma in the study tooth
* Systemic diseases that may affect neuropeptide levels (e.g., diabetes mellitus, thyroid disorders, renal or hepatic disease)
* Use of medications affecting salivary flow
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kahramanmaras Sutcu Imam University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aliye Kamalak
Assoc. Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kahramanmaraş Sutcu İmam University, Faculty of Dentistry
Kahramanmaraş, onikişubat, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRÜ/24.15.46
Identifier Type: OTHER
Identifier Source: secondary_id
HRÜ/24.15.46
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.